Bioengineered angiotensin-converting-enzyme-2: a potential therapeutic option against SARS-CoV-2 infection

The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. The bioengineered ACE2 (Tag-sACE2 and probiotic-ACE2) as a way may overcome its therapeutic lim...

Descripción completa

Detalles Bibliográficos
Autor principal: Maiti, Biplab K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589099/
https://www.ncbi.nlm.nih.gov/pubmed/34773078
http://dx.doi.org/10.1038/s41371-021-00636-y
Descripción
Sumario:The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. The bioengineered ACE2 (Tag-sACE2 and probiotic-ACE2) as a way may overcome its therapeutic limitations against ongoing current pandemic.

Ejemplares similares